Literature DB >> 15779232

Reduced apoptosis rates in human schwannomas.

Tamara Utermark1, Katherine Kaempchen, Gregor Antoniadis, C Oliver Hanemann.   

Abstract

Schwannomas, tumors originating from Schwann cells, represent a frequent neurological tumor and can occur both in a genetic disorder called neurofibromatosis type 2 (NF2) and sporadically. In both cases the genetic background is identical as all schwannomas are caused by biallelic mutations in the tumor suppressor gene NF2 coding for merlin. Mutations in this gene have also been found to be responsible for 50% to 60% of spontaneous and 100% of the NF2 associated meningiomas. The NF2 gene product, merlin, links transmembrane proteins to the cytoskeleton and is involved in intracellular signaling processes. It has previously been shown that reexpression of wild-type merlin in primary human schwannoma cells leads to an increase in the number of apoptotic cells. Here, we report in vivo and in vitro evidence that the basal apoptosis rate of primary human schwannoma cells is reduced in comparison to that of normal Schwann cells, supporting the idea that in this benign tumor type, apoptosis has a role in tumorigenesis.

Entities:  

Mesh:

Year:  2005        PMID: 15779232     DOI: 10.1111/j.1750-3639.2005.tb00095.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  6 in total

1.  What are the hallmarks of cancer?

Authors:  Yuri Lazebnik
Journal:  Nat Rev Cancer       Date:  2010-04       Impact factor: 60.716

2.  ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

Authors:  Sylwia Ammoun; Clare H Cunliffe; Jeffrey C Allen; Luis Chiriboga; Filippo G Giancotti; David Zagzag; C Oliver Hanemann; Matthias A Karajannis
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

3.  PAK kinase regulates Rac GTPase and is a potential target in human schwannomas.

Authors:  Christine Flaiz; Jonathan Chernoff; Sylwia Ammoun; Jeffrey R Peterson; Clemens O Hanemann
Journal:  Exp Neurol       Date:  2009-05-03       Impact factor: 5.330

4.  The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Lu Zhou; David A Hilton; Magdalena Barczyk; Clemens Oliver Hanemann
Journal:  Mol Oncol       Date:  2014-08-27       Impact factor: 6.603

5.  Primary culture of human Schwann and schwannoma cells: improved and simplified protocol.

Authors:  Sonam Dilwali; Pratik B Patel; Daniel S Roberts; Gina M Basinsky; Gordon J Harris; Kevin S Emerick; Konstantina M Stankovic
Journal:  Hear Res       Date:  2014-06-06       Impact factor: 3.208

6.  Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.

Authors:  Sylwia Ammoun; Marei Caroline Schmid; Joceline Triner; Paul Manley; Clemens Oliver Hanemann
Journal:  Neuro Oncol       Date:  2011-07       Impact factor: 12.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.